🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,046 results for “infusion” Clear

  1. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    The George Institute

    relapsed/refractory Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  2. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Maplirpacept

    Pfizer Australia Pty Ltd

    Relapsed/Refractory Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  3. Columvi 10 mg concentrate for solution for infusion, Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)

    phase 2 small molecule active

    1 trial

  4. Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Graft Versus Host Disease

    phase 2 other completed

    1 trial

  5. Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Rilvegostomig

    AstraZeneca AB

    metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  6. Cyramza 10 mg/ml concentrate for solution for infusion, PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer stage IV with metastases

    phase 2 small molecule active

    1 trial

  7. DARZALEX 20 mg/mL concentrate for solution for infusion, DARZALEX 1800 mg solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, VELCADE 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Venetoclax, DEXAMETHASONE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  8. DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Empliciti 400 mg powder for concentrate for solution for infusion., Dexamethason CF 20 mg/ml, injectievloeistof, Dexamethasone 2mg Tablets, VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, Dexamethason 4 mg JENAPHARM®, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, CC-92480, CC-92480

    Celgene Europe Limited

    Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)

    phase 2 small molecule active

    1 trial

  9. DC-VACCINE_IRSTIRCCS, Proleukin 18 x 106 UI Polvere per soluzione iniettabile o per infusione

    Istituto Gentili S.r.l.

    Stage IV colorectal cancer

    phase 2 small molecule active

    1 trial

  10. DEGARELIX ACETATE, ENZALUTAMIDE, DEGARELIX, ENZALUTAMIDE, DAROLUTAMIDE, RELUGOLIX, -, ENZALUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, Pluvicto 1 000 MBq/mL solution for injection/infusion, APALUTAMIDE

    Novartis Pharmaceuticals

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  11. DEXAMETHASONE , ENFORTUMAB VEDOTIN , -, PARACETAMOL , -, MK-2870, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  12. DEXAMETHASONE , PEGFILGRASTIM , Mosunetuzumab, DIPHENHYDRAMINE , RASBURICASE , Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, PREDNISONE , FLUDEOXYGLUCOSE (18F) , METHYLPREDNISOLONE, MabThera 500 mg concentrate for solution for infusion, PARACETAMOL, ALLOPURINOL

    Hoffmann-La Roche

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  13. DEXAMETHASONE, DEXAMETHASONE, LENALIDOMIDE, Empliciti 400 mg powder for concentrate for solution for infusion., LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE

    Bristol-Myers Squibb Australia Pty Ltd

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  14. DOCETAXEL , PACLITAXEL , GEMCITABINE , VINORELBINE , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., PEMETREXED , Inflectra 100 mg powder for concentrate for solution for infusion, Micofenolato de mofetil Generis 250 mg Cápsulas

    AstraZeneca AB

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  15. DOCETAXEL , PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , CETUXIMAB, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Recurrent or metastatic squamous cell carcinoma of the head and neck

    phase 2 small molecule active

    1 trial

  16. DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CYCLOPHOSPHAMIDE , PACLITAXEL , EPIRUBICIN , CARBOPLATIN , MK-1022, CAPECITABINE , OLAPARIB

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

  17. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Ningbo Cancer Hospital

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  18. Dacogen 50 mg powder for concentrate for solution for infusion., Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets

    Fondazione Telethon ETS

    Acute Myeloid Leukemia secondary to myeloproliferative neoplasms

    phase 2 small molecule active

    1 trial

  19. Dectova 10 mg/mL solution for infusion

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  20. Defosbarasertib, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    First-line patients with extensive disease small-cell lung cancer (SCLC)

    phase 2 small molecule active

    1 trial

  21. Dexamethason 4 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, CRISANTASPASE, Dexamethason 0,5 mg JENAPHARM®, Vincristine Sulfate 1 mg/ml solution for injection, Oncaspar 750 U/ml powder for solution for injection/infusion., Dexamethasone 3.3 mg/mL Solution for injection, MITOXANTRONE HYDROCHLORIDE, BESPONSA 1 mg powder for concentrate for solution for infusion

    Pfizer Australia Pty Ltd

    Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  22. Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  23. Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Dexamethason 4 mg JENAPHARM®, teclistamab, teclistamab, Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 2 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Pomalidomide, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Im

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  24. Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Paracetamol 500 mg Film-Coated Tablets, Diluent for REGN5458, Linvoseltamab, Diphenhydramine Hydrochloride 25 mg Tablets, Dermodrin 30 mg/2 ml soluție injectabilă, Dexamethasone 4 mg tablets, RoActemra 20 mg/mL concentrate for solution for infusion, Linvoseltamab

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources